LAXATIVE- bisacodyl tablet 
Allegiant Health

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

226 - Health A2Z Bisacodyl 5mg

Active Ingredient (in each tablet)

Bisacodyl USP 5mg

Purpose

Stimulant Laxative

Uses

  • for temporary relief of occasional constipation and irregularity
  • this product generally produces bowel movement in 6 to 12 hours

Warnings

Do not use

if you cannot swallow without chewing.

Ask a doctor before use if you have

  • stomach pain, nausea or vomiting
  • a sudden change in bowel habits that lasts more than 2 weeks

When using this product

  • do not chew or crush tablet(s)
  • do not use within 1 hour after taking an antacid or milk
  • it may cause stomach discomfort, faintness and cramps

Stop use and ask a doctor if

  • you have rectal bleeding or no bowel movement after using this product

These could be signs of a serious condition.

  • you need to use a laxative for more than 1 week

If pregnant or breast-feeding

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children

Keep out of reach of children. In case of accidental overdose, get medical help or contact a doctor or Poison Control Center 

(1-800-222-1222) right away.

Directions

  • take with a glass of water

Adults and children 12 years of age and over: 1 to 3 tablets in a single daily dose

Children 6 to under 12 years of age: 1 tablet in a single daily dose

Children under 6 years of age: ask a doctor

Other information

  • store between 68º to 77ºF (20º to 25ºC)
  • do not use blister unit is broken or torn  

Inactive ingredients

acacia, calcium sulfate anhydrous, carnauba wax, corn starch, D&C yellow #10 aluminum lake, FD&C yellow #6 aluminum lake, gelatin, iron oxide black, iron oxide red, iron oxide yellow, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polyvinyl acetate phthalate, povidone, shellac, silicon dioxide, sodium starch glycolate, stearic acid, sugar, talc, titanium dioxide

Principal Display Panel

HealthA2Z®

*Compare To Ducolax® Active Ingredients

Laxative

Bisacodyl 5mg

Gentle & Effective 

Overnight Relief

Enteric Coated

TABLETS 

Bisacodyl 5mg Tablets

Bisacodyl 5mg Tablets

LAXATIVE 
bisacodyl tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:69168-226
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BISACODYL (UNII: 10X0709Y6I) (DEACETYLBISACODYL - UNII:R09078E41Y) BISACODYL5 mg
Inactive Ingredients
Ingredient NameStrength
ACACIA (UNII: 5C5403N26O)  
CALCIUM SULFATE ANHYDROUS (UNII: E934B3V59H)  
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
CARNAUBA WAX (UNII: R12CBM0EIZ)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
STARCH, CORN (UNII: O8232NY3SJ)  
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
GELATIN (UNII: 2G86QN327L)  
FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)  
Polyvinyl Acetate Phthalate (UNII: 58QVG85GW3)  
POVIDONE (UNII: FZ989GH94E)  
SHELLAC (UNII: 46N107B71O)  
SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B)  
STEARIC ACID (UNII: 4ELV7Z65AP)  
SUGARCANE (UNII: 81H2R5AOH3)  
TALC (UNII: 7SEV7J4R1U)  
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
Product Characteristics
ColororangeScoreno score
ShapeROUNDSize5mm
FlavorImprint Code TCL003
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:69168-226-9225 in 1 BLISTER PACK; Type 0: Not a Combination Product12/23/201408/31/2020
2NDC:69168-226-03250 in 1 BOTTLE; Type 0: Not a Combination Product12/23/201408/31/2020
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph not finalpart33412/23/201408/31/2020
Labeler - Allegiant Health (079501930)

Revised: 11/2017
 
Allegiant Health